Episode Details

Back to Episodes
Perspectives on the safety of a JAK inhibitor in RA, PsA, and AS – Featuring Drs Wickersham, Winthrop, and Ritchlin Sponsored by AbbVie Medical Affairs

Perspectives on the safety of a JAK inhibitor in RA, PsA, and AS – Featuring Drs Wickersham, Winthrop, and Ritchlin Sponsored by AbbVie Medical Affairs

Episode 947 Published 3 years, 8 months ago
Description

Drs. Pendleton Wickersham (Arthritis Associates PA, San Antonio, TX), Kevin Winthrop (OHSU, Portland, OR), and Christopher Ritchlin (URMC, Rochester, NY) come together to share their experiences discussing with patients the benefit-risk of a JAK inhibitor.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us